Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16
Tamotsu Sagawa,Akihito Tsuji,Hironaga Satake,Masato Nakamura,Yu Sunakawa,Shotaro Korehisa,Masato Matsuura,Yasuhiro Yuasa,Takashi Mine,Hiroaki Nagano,Kunitoshi Shigeyasu,Tatsuya Kinjo,Masahito Kotaka,Hiroyuki Okuyama,Yutaro Kubota,Mitsugu Kochi,Toshiki Masuishi,Masahiro Takeuchi,Wataru Ichikawa,Masashi Fujii ANNALS OF ONCOLOGY（2022）
AI 理解论文
溯源树
样例
